JP2006506414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506414A5 JP2006506414A5 JP2004549780A JP2004549780A JP2006506414A5 JP 2006506414 A5 JP2006506414 A5 JP 2006506414A5 JP 2004549780 A JP2004549780 A JP 2004549780A JP 2004549780 A JP2004549780 A JP 2004549780A JP 2006506414 A5 JP2006506414 A5 JP 2006506414A5
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- combination
- inhibitor
- inflammation
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- KAVIOGXCVVZYEM-SMDDNHRTSA-N (4s)-4-[(2r)-2-[2-chloro-5-(trifluoromethyl)phenyl]sulfanyl-2-(1,3-thiazol-5-yl)ethyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid Chemical compound OC(=O)N1C(C)(C)OC[C@@H]1C[C@H](C=1SC=NC=1)SC1=CC(C(F)(F)F)=CC=C1Cl KAVIOGXCVVZYEM-SMDDNHRTSA-N 0.000 description 1
- -1 4-chloro-3-fluorobenzoyl triflate Chemical compound 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Description
本発明の化合物はまた、第２の薬学的に活性な物質と組み合わせて；特にシクロオキシゲナーゼ阻害剤と組み合わせて；さらに特定的には誘導型シクロオキシゲナーゼ(ＣＯＸ−２)のアイソフォームの選択的阻害剤と組み合わせて、有利に用いられ得る。従って、本発明のさらなる態様において、炎症、炎症性疾患、および炎症関連疾患を処置するためのＣＯＸ−２阻害剤と組み合わせた、式(Ｉ)の化合物またはその薬学的に許容される塩の使用が提供される。さらにまた、炎症、炎症性疾患、および炎症関連疾患もしくは状態を有しもしくはそのリスクを有するヒトにおいて、炎症、炎症性疾患、および炎症関連疾患を処置しもしくはそのリスクを軽減する方法であって、該方法が、ＣＯＸ−２阻害剤と組み合わせた、式(Ｉ)の化合物またはその薬学的に許容される塩を、治療上効果的な量で、該ヒトに投与することを含む方法が提供される。
中間体化合物は、そのまままたは保護された形態で用いられ得る。保護基およびその除去方法の詳細は、標準的なテキストである“Protective Groups in Organic Synthesis”, 3rd Edition (1999) by Greene and Wuts を参照して見出され得る。
本化合物およびその薬学的に許容される塩は、一酸化窒素合成酵素の合成もしくは過剰合成が寄与する部分のある疾患もしくは状態の処置または予防に使用するために適応される。特に、本化合物は、ヒトを含む哺乳動物において、炎症状態の処置に使用するために適応される。
実施例３
(２Ｓ,４Ｒ)−２−アミノ−４−[[２−クロロ−５−(トリフルオロメチル)フェニル]チオ]−５−チアゾールブタノール塩酸塩
ａ) (４Ｓ)−４−[(２Ｒ)−２−[[２−クロロ−５−(トリフルオロメチル)フェニル]チオ]−２−(５−チアゾリル)エチル]−２,２−ジメチル−３−オキサゾリジンカルボン酸, １,１−ジメチルエチル エステル
実施例１の段階(ｃ)の生成物(１９０mg)を、４−クロロ−３−フルオロベンゾトリフルオリド(８３mg)と炭酸セシウム(１６３mg)で、実施例１の段階(ｄ)の手順に従って処理し、副題化合物を粘稠な油状物として得た(１０５mg)。
MS APCI +ve m/z 523 ([M+H]+).
(２Ｓ,４Ｒ)−２−アミノ−４−[[２−クロロ−５−(トリフルオロメチル)フェニル]チオ]−５−チアゾールブタノール塩酸塩
ａ) (４Ｓ)−４−[(２Ｒ)−２−[[２−クロロ−５−(トリフルオロメチル)フェニル]チオ]−２−(５−チアゾリル)エチル]−２,２−ジメチル−３−オキサゾリジンカルボン酸, １,１−ジメチルエチル エステル
実施例１の段階(ｃ)の生成物(１９０mg)を、４−クロロ−３−フルオロベンゾトリフルオリド(８３mg)と炭酸セシウム(１６３mg)で、実施例１の段階(ｄ)の手順に従って処理し、副題化合物を粘稠な油状物として得た(１０５mg)。
MS APCI +ve m/z 523 ([M+H]+).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0203304A SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Novel Coumpounds |
| PCT/SE2003/001712 WO2004041794A1 (en) | 2002-11-07 | 2003-11-06 | Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506414A JP2006506414A (ja) | 2006-02-23 |
| JP2006506414A5 true JP2006506414A5 (ja) | 2006-12-21 |
Family
ID=20289508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004549780A Withdrawn JP2006506414A (ja) | 2002-11-07 | 2003-11-06 | 抗炎症性３−アリールチオ−３−チアゾリル−アルキルアミン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060040992A1 (ja) |
| EP (1) | EP1562920B1 (ja) |
| JP (1) | JP2006506414A (ja) |
| AT (1) | ATE331711T1 (ja) |
| AU (1) | AU2003278667A1 (ja) |
| DE (1) | DE60306546T2 (ja) |
| ES (1) | ES2268441T3 (ja) |
| SE (1) | SE0203304D0 (ja) |
| WO (1) | WO2004041794A1 (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035700A1 (es) * | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| CN101827852B (zh) | 2007-10-19 | 2014-07-30 | 贝林格尔.英格海姆国际有限公司 | 取代的哌啶子基-二氢噻吩并嘧啶 |
| WO2010070032A1 (en) | 2008-12-19 | 2010-06-24 | Boehringer Ingelheim International Gmbh | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
| WO2011073155A1 (en) | 2009-12-17 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Novel antagonists for ccr2 and uses thereof |
| MX346393B (es) | 2009-12-17 | 2017-03-17 | Centrexion Therapeutics Corp | Nuevos antagonistas del receptor ccr2 y usos de los mismo. |
| EP2528915B1 (en) | 2010-01-29 | 2015-10-28 | Boehringer Ingelheim International GmbH | Substituted naphthyridines and their use as syk kinase inhibitors |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
| WO2012101013A1 (en) | 2011-01-28 | 2012-08-02 | Boehringer Ingelheim International Gmbh | Substituted pyridinyl-pyrimidines and their use as medicaments |
| WO2012171863A1 (en) | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| EP2736886B1 (en) | 2011-07-26 | 2016-09-14 | Boehringer Ingelheim International GmbH | Substituted quinolines and their use as medicaments |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| CN110183440B (zh) | 2014-03-19 | 2022-04-22 | 勃林格殷格翰国际有限公司 | 杂芳基syk抑制剂 |
| GB201512635D0 (en) | 2015-07-17 | 2015-08-26 | Ucl Business Plc | Uses of therapeutic compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2688638A (en) * | 1951-07-17 | 1954-09-07 | Givaudan Corp | Nu-(beta-phenoxyethyl) haloethylamines |
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| FR2432500A1 (fr) * | 1978-02-24 | 1980-02-29 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments |
| US4330546A (en) * | 1979-09-14 | 1982-05-18 | John Wyeth & Brother Limited | 3-Aryl-3-aryloxypropylamines |
| DE3138550A1 (de) * | 1981-09-28 | 1983-04-07 | Boehringer Ingelheim KG, 6507 Ingelheim | Substituierte 2-phenyl-2-(pyridyloxy)-ethylamine und isostere verbindungen, verfahren zu ihrer herstellung und verwendung |
| DE3328348A1 (de) * | 1983-08-05 | 1985-02-14 | Degussa Ag, 6000 Frankfurt | Verfahren zur duennschichtchromatographischen trennung von enantiomeren |
| US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| GB0004153D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| GB0004151D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| GB0004152D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
| GB0004149D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
| AR035700A1 (es) * | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| SE0102640D0 (sv) * | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
| SE0102641D0 (sv) * | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
| PL393941A1 (pl) * | 2001-11-21 | 2011-06-20 | University Of Aarhus | Zastosowanie glikozydów mono-i diacyloglicerolu jako środków przeciwzapalnych |
-
2002
- 2002-11-07 SE SE0203304A patent/SE0203304D0/xx unknown
-
2003
- 2003-11-06 EP EP03770201A patent/EP1562920B1/en not_active Expired - Lifetime
- 2003-11-06 ES ES03770201T patent/ES2268441T3/es not_active Expired - Lifetime
- 2003-11-06 AT AT03770201T patent/ATE331711T1/de not_active IP Right Cessation
- 2003-11-06 AU AU2003278667A patent/AU2003278667A1/en not_active Abandoned
- 2003-11-06 JP JP2004549780A patent/JP2006506414A/ja not_active Withdrawn
- 2003-11-06 US US10/534,191 patent/US20060040992A1/en not_active Abandoned
- 2003-11-06 WO PCT/SE2003/001712 patent/WO2004041794A1/en active IP Right Grant
- 2003-11-06 DE DE60306546T patent/DE60306546T2/de not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006506414A5 (ja) | ||
| RU2335493C2 (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| BRPI0414581B8 (pt) | composto, composição farmacêutica compreendendo o referido composto e uso do referido composto | |
| RU2005141226A (ru) | Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью | |
| WO2004009558A3 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
| NO20075042L (no) | Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer | |
| DOP2004001052A (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| BR9710372A (pt) | Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase | |
| NO308130B1 (no) | Arylsylfonamidosubstituerte hydroksaminsyrer som matriksmetalloproteinasehemmere samt anvendelse av samme for fremstilling av medikament | |
| WO2007078874A3 (en) | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors | |
| WO2005030766A8 (en) | Phenyl - carboxamide compounds useful for treating pain | |
| RU2010107892A (ru) | Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их | |
| DK0699439T3 (da) | Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer | |
| MY145329A (en) | Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BR9809022A (pt) | Composições antiinflamatórias nasais tópicas | |
| RU2004114560A (ru) | Комбинации, включающие ингибиторы сох-2 и аспирин | |
| CO5011084A1 (es) | Composiciones y metodos para tratar trastornos respiratorios | |
| RU2007138263A (ru) | Противовоспалительные соединения | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| CA2438799A1 (en) | Preventative of therapeutic agent for inflammatory respiratory tract disease | |
| RU98119076A (ru) | Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2 | |
| BR9304211A (pt) | Composto, processo para iduzir imunossupressçao, composiçao farmacêueica e processo para produzir o dito composto | |
| CZ63295A3 (en) | 1 alpha-fluoro-25-hydroxy-16-en-23-in-cholecalciferol as such and for the use as a therapeutic active compound, its use for the preparation of a pharmaceutical preparation, process of its preparation and a pharmaceutical preparation based thereon | |
| BRPI0517084A (pt) | composto de éster, composição farmacêutica, inibidor da proteìna de transferência de triglicerìdeo microssÈmico, agente de diminuição de pelo menos um dos parámetros lipìdicos do sangue, método para o tratamento ou profilaxia de uma doença, embalagem comercial, e, uso do composto de éster |